ArcticZymes Technologies Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
ArcticZymes Technologies wird ein jährliches Gewinn- und Umsatzwachstum von 46% bzw. 14.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 46.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.4% betragen.
Wichtige Informationen
46.0%
Wachstumsrate der Gewinne
46.34%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 22.8% |
| Wachstumsrate der Einnahmen | 14.7% |
| Zukünftige Eigenkapitalrendite | 9.43% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 31 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Apr 27
AZT: Enzyme Platform Expansion And Investor Day Will Support Future Upside
Analysts have slightly reduced their price target on ArcticZymes Technologies from NOK 32.50 to NOK 32.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation (Key Developments).Narrativ-Update • Apr 12
AZT: Enzyme Platform Scaling And Analyst Day Will Support Future Upside
Analysts now keep their price target for ArcticZymes Technologies steady at NOK 32.50, reflecting largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their models. What's in the News ArcticZymes Technologies plans an Analyst/Investor Day to outline how the company has completed its commercial transformation and is now focused on scaling its enzyme platform across biomanufacturing and molecular tool markets (Key Developments).Narrativ-Update • Mar 29
AZT: Enzyme Platform Scaling Across Biomanufacturing And Molecular Tools Will Drive Future Upside
Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.5, noting only minor adjustments to factors such as the discount rate, revenue growth assumptions and future P/E that do not materially affect their overall assessment of fair value. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation.Narrativ-Update • Mar 14
AZT: Enzyme Platform Scaling Across Biomanufacturing Markets Will Support Future Upside
Analysts have slightly adjusted their price target for ArcticZymes Technologies to NOK 32.50, reflecting modest tweaks to their discount rate, revenue growth expectations, profit margin assumptions, and future P/E inputs, while keeping their overall fair value view unchanged. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day to explain how it has completed its commercial transformation.Narrativ-Update • Feb 27
AZT: Enzyme Platform Scaling Across Biomanufacturing Will Drive Future Upside
Analysts have trimmed their price target for ArcticZymes Technologies to NOK 32.5 from NOK 40.20. They cite slightly lower assumptions for long term revenue growth, profit margin and future P/E, along with a modestly higher discount rate in their models.Analyseartikel • Feb 15
Results: ArcticZymes Technologies ASA Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, ArcticZymes Technologies ASA ( OB:AZT ) just kicked off its latest full-year results with some very...Narrativ-Update • Feb 13
AZT: Buyback Program And Platform Scaling Will Support Future Upside
Analysts have nudged their price target for ArcticZymes Technologies to NOK32.50 from NOK32.00, reflecting updated views on slightly adjusted revenue growth, profit margin assumptions and a higher future P/E multiple. What's in the News ArcticZymes Technologies plans an Analyst and Investor Day to explain how it has completed its commercial transformation and is now focused on scaling its enzyme platform across high growth biomanufacturing and molecular tool markets (Key Developments).Narrativ-Update • Jan 23
AZT: European Distribution Deal And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for ArcticZymes Technologies steady at NOK 32.0 per share, indicating only minor adjustments in assumptions such as the discount rate and future P/E, rather than any major change in their overall view. What's in the News ArcticZymes Technologies ASA plans to start share repurchases on November 25, 2025, under an AGM mandate from May 27, 2025.Analyseartikel • Jan 08
Subdued Growth No Barrier To ArcticZymes Technologies ASA (OB:AZT) With Shares Advancing 25%
Those holding ArcticZymes Technologies ASA ( OB:AZT ) shares would be relieved that the share price has rebounded 25...Narrativ-Update • Jan 07
AZT: European Distribution Agreement And Share Buyback Will Support Future Upside
Analysts have maintained their fair value estimate for ArcticZymes Technologies at $32.0. They cite unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for leaving their price target intact. What's in the News ArcticZymes Technologies ASA started a share repurchase program on November 25, 2025, under an authorization from the May 27, 2025 Annual General Meeting.Analyseartikel • Jan 07
Are Investors Undervaluing ArcticZymes Technologies ASA (OB:AZT) By 50%?
Key Insights The projected fair value for ArcticZymes Technologies is kr45.44 based on 2 Stage Free Cash Flow to Equity...Narrativ-Update • Dec 23
AZT: European Distribution Deal And Buyback Program Will Drive Future Upside
Analysts have modestly raised their price target on ArcticZymes Technologies to NOK 32.00, reflecting slightly lower perceived risk and continued confidence in the company’s robust growth and margin profile. What's in the News ArcticZymes Technologies has commenced a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90 percent of outstanding share capital.Narrativ-Update • Dec 09
AZT: European Distribution Deal Will Drive Future Demand And Margin Strength
Narrative Update on ArcticZymes Technologies Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.00, reflecting largely unchanged assumptions on fair value, revenue growth, and profit margins, while only slightly adjusting the discount rate and future price to earnings expectations. What's in the News ArcticZymes Technologies ASA has launched a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90% of outstanding capital, with authorization valid until the 2026 AGM or June 30, 2026, whichever comes first (Key Developments).Narrativ-Update • Nov 25
AZT: Exclusive Distribution Partnership Will Drive European Expansion And Strengthen Margins
Analysts have adjusted their price target for ArcticZymes Technologies, keeping it at NOK 32.00. This decision is based on continued expectations for strong profit margins along with a more cautious perspective on future earnings multiples.Analyseartikel • Nov 20
More Unpleasant Surprises Could Be In Store For ArcticZymes Technologies ASA's (OB:AZT) Shares After Tumbling 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...Narrativ-Update • Nov 10
AZT: Exclusive Distribution Deal Will Improve Profitability And European Market Presence
Analysts have maintained their fair value estimate for ArcticZymes Technologies at NOK 32.00, citing stable profit margin improvements and changes in the revenue growth outlook as key factors in their latest assessment. What's in the News ArcticZymes Technologies ASA and Brenntag Specialties Pharma have signed an exclusive distribution agreement for SAN-HQ and M-SAN enzymes across Europe.Narrativ-Update • Oct 27
Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies
Analysts have maintained their fair value price target for ArcticZymes Technologies at NOK 32.00. They cite stable revenue growth and profitability projections as the basis for leaving their outlook unchanged.Narrativ-Update • Oct 13
Biomanufacturing And Gene Therapies Will Expand Precision Medicine
Analysts have raised their price target for ArcticZymes Technologies from NOK 29 to NOK 32. They cite updated growth forecasts and stronger margin expectations as key factors in the upward revision.Narrativ-Update • Aug 15
Biomanufacturing Advances Will Unlock Global Market Access
The significant increase in consensus analyst price target for ArcticZymes Technologies is primarily driven by notably higher forecasts for revenue growth and a rising future P/E multiple, resulting in an upward revision from NOK17.50 to NOK24.50. What's in the News Launched M-SAN HQ GMP, a new GMP-grade nuclease tailored for viral vector manufacturing, enabling high activity in physiological salt conditions and improving DNA removal without harsh buffers.Analyseartikel • Aug 15
What ArcticZymes Technologies ASA's (OB:AZT) 50% Share Price Gain Is Not Telling You
ArcticZymes Technologies ASA ( OB:AZT ) shareholders have had their patience rewarded with a 50% share price jump in...Analyseartikel • Mar 11
ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up
The ArcticZymes Technologies ASA ( OB:AZT ) share price has done very well over the last month, posting an excellent...Analyseartikel • Feb 15
ArcticZymes Technologies ASA's (OB:AZT) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights The projected fair value for ArcticZymes Technologies is kr27.08 based on 2 Stage Free Cash Flow to Equity...
Neues Narrativ • Jan 20
Transition To Solution Provider Will Accelerate Market Penetration By Late 2025
ArcticZymes is shifting from raw materials to solutions, aiming for revenue growth through closer customer interactions and market penetration by late 2025.Analyseartikel • Nov 28
Take Care Before Jumping Onto ArcticZymes Technologies ASA (OB:AZT) Even Though It's 25% Cheaper
To the annoyance of some shareholders, ArcticZymes Technologies ASA ( OB:AZT ) shares are down a considerable 25% in...Analyseartikel • Nov 12
Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Market forces rained on the parade of ArcticZymes Technologies ASA ( OB:AZT ) shareholders today, when the analysts...Analyseartikel • Nov 09
ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its...Analyseartikel • Aug 31
The Price Is Right For ArcticZymes Technologies ASA (OB:AZT) Even After Diving 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...Analyseartikel • Aug 30
ArcticZymes Technologies' (OB:AZT) Solid Earnings May Rest On Weak Foundations
ArcticZymes Technologies ASA's ( OB:AZT ) healthy profit numbers didn't contain any surprises for investors. We think...Analyseartikel • Aug 25
ArcticZymes Technologies ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a sad week for ArcticZymes Technologies ASA ( OB:AZT ), who've watched their investment drop 13% to kr21.00...Analyseartikel • May 12
Earnings Miss: ArcticZymes Technologies ASA Missed EPS By 17% And Analysts Are Revising Their Forecasts
Last week, you might have seen that ArcticZymes Technologies ASA ( OB:AZT ) released its quarterly result to the...Analyseartikel • Feb 08
ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Last week's earnings announcement from ArcticZymes Technologies ASA ( OB:AZT ) was disappointing to investors, with a...Analyseartikel • Feb 04
ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its yearly...Analyseartikel • Feb 02
Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
When close to half the companies operating in the Biotechs industry in Norway have price-to-sales ratios (or "P/S...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 190 | 48 | 56 | 59 | 2 |
| 12/31/2027 | 162 | 33 | 39 | 42 | 2 |
| 12/31/2026 | 137 | 18 | 20 | 23 | 2 |
| 3/31/2026 | 128 | 13 | 23 | 27 | N/A |
| 12/31/2025 | 118 | 10 | 22 | 26 | N/A |
| 9/30/2025 | 110 | 7 | 18 | 22 | N/A |
| 6/30/2025 | 104 | 3 | 5 | 11 | N/A |
| 3/31/2025 | 103 | 2 | -1 | 5 | N/A |
| 12/31/2024 | 108 | 8 | -8 | 2 | N/A |
| 9/30/2024 | 111 | 5 | -8 | 7 | N/A |
| 6/30/2024 | 118 | 13 | 0 | 20 | N/A |
| 3/31/2024 | 118 | 18 | 7 | 28 | N/A |
| 12/31/2023 | 120 | 19 | 5 | 24 | N/A |
| 9/30/2023 | 119 | 20 | 7 | 27 | N/A |
| 6/30/2023 | 118 | 16 | 8 | 25 | N/A |
| 3/31/2023 | 120 | 17 | 20 | 36 | N/A |
| 12/31/2022 | 138 | 33 | 46 | 58 | N/A |
| 9/30/2022 | 150 | 47 | 56 | 64 | N/A |
| 6/30/2022 | 147 | 52 | 58 | 68 | N/A |
| 3/31/2022 | 139 | 48 | 55 | 65 | N/A |
| 12/31/2021 | 131 | 46 | 63 | 75 | N/A |
| 9/30/2021 | 114 | 68 | 54 | 64 | N/A |
| 6/30/2021 | 108 | 67 | 57 | 61 | N/A |
| 3/31/2021 | 120 | 84 | 63 | 66 | N/A |
| 12/31/2020 | 98 | 74 | 45 | 47 | N/A |
| 9/30/2020 | 64 | 43 | 48 | 50 | N/A |
| 6/30/2020 | 68 | 37 | 37 | 39 | N/A |
| 3/31/2020 | 88 | 8 | 10 | 12 | N/A |
| 12/31/2019 | 49 | -1 | N/A | 4 | N/A |
| 9/30/2019 | 80 | -9 | N/A | -1 | N/A |
| 6/30/2019 | 79 | -10 | N/A | -9 | N/A |
| 3/31/2019 | 73 | -13 | N/A | -7 | N/A |
| 12/31/2018 | 73 | -14 | N/A | -15 | N/A |
| 9/30/2018 | 70 | -20 | N/A | -22 | N/A |
| 6/30/2018 | 63 | -27 | N/A | -21 | N/A |
| 3/31/2018 | 69 | -27 | N/A | -23 | N/A |
| 12/31/2017 | 73 | -25 | N/A | -22 | N/A |
| 9/30/2017 | 74 | -26 | N/A | -23 | N/A |
| 6/30/2017 | 80 | -24 | N/A | -22 | N/A |
| 3/31/2017 | 79 | -21 | N/A | -18 | N/A |
| 12/31/2016 | 79 | -20 | N/A | -19 | N/A |
| 9/30/2016 | 78 | -20 | N/A | -14 | N/A |
| 6/30/2016 | 72 | -19 | N/A | -13 | N/A |
| 3/31/2016 | 66 | -18 | N/A | -14 | N/A |
| 12/31/2015 | 59 | -17 | N/A | -13 | N/A |
| 9/30/2015 | 55 | -15 | N/A | -14 | N/A |
| 6/30/2015 | 48 | -16 | N/A | -17 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: AZTDas prognostizierte Gewinnwachstum (46% pro Jahr) liegt über der Sparquote (3.3%).
Ertrag vs. Markt: AZTDie Erträge des Unternehmens (46% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Norwegian (9.7% pro Jahr).
Hohe Wachstumserträge: AZTEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: AZTDie Einnahmen des Unternehmens (14.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Norwegian (2.1% pro Jahr).
Hohe Wachstumseinnahmen: AZTDie Einnahmen des Unternehmens (14.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: AZTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.4%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/11 00:15 |
| Aktienkurs zum Tagesende | 2026/06/11 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
ArcticZymes Technologies ASA wird von 6 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Carnegie |
| Viktor Sundberg | Nordea Markets |